Trastuzumab Deruxtecan Shows Clinically Meaningful Response in Non-Small Cell Lung Cancer
September 13th 2022Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.
No Benefit to Postoperative Radiotherapy in Patients With Non-small Cell Lung Cancer
September 28th 2020At ESMO 2020, researchers discussed some long-awaited data regarding postoperative radiotherapy used in patients with non-small cell lung cancer following complete resection and after (neo) adjuvant chemotherapy.